| The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy U Sengupta, AN Nilson, R Kayed EBioMedicine 6, 42-49, 2016 | 761 | 2016 |
| Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases AN Nilson, KC English, JE Gerson, T Barton Whittle, C Nicolas Crain, ... Journal of Alzheimer's Disease 55 (3), 1083-1099, 2017 | 171 | 2017 |
| Cerebral microvascular accumulation of tau oligomers in Alzheimer’s disease and related tauopathies DL Castillo-Carranza, AN Nilson, CE Van Skike, JB Jahrling, K Patel, ... Aging and disease 8 (3), 257, 2017 | 108 | 2017 |
| The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6: 42–49 U Sengupta, AN Nilson, R Kayed | 46 | 2016 |
| The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine. 2016; 6: 42–9 U Sengupta, AN Nilson, R Kayed Epub 2016/05/24. https://doi. org/10.1016/j. ebiom. 2016. 03.035 PMID: 27211547, 0 | 18 | |
| Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder CA Boateng, AN Nilson, R Placide, ML Pham, FM Jakobs, N Boldizsar, ... Journal of Medicinal Chemistry 66 (17), 12141-12162, 2023 | 2 | 2023 |
| G Protein Biased Signaling by Non‐catechol Dopamine D1 Receptor Agonists AN Nilson, P Wang, MK Jain, J Zhou, JA Allen The FASEB Journal 34 (S1), 1-1, 2020 | 2 | 2020 |
| Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical … RB Free, AN Nilson, NM Boldizsar, TB Doyle, RM Rodriguiz, ... ACS Pharmacology & Translational Science 6 (1), 151-170, 2022 | 1 | 2022 |
| Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders AN Nilson, DE Felsing, JA Allen GPCRs as Therapeutic Targets 2, 677-731, 2022 | 1 | 2022 |
| Functionally selective receptor signaling and endocytosis by dopamine D1 receptor agonists AN Nilson | 1 | 2020 |
| β‐arrestins mediate rapid 5‐HT2A receptor endocytosis to regulate intensity and duration of signaling DE Felsing, A Nilson, M Jain, S Raval, A Inoue, J Allen The FASEB Journal 33 (S1), 502.3-502.3, 2019 | 1 | 2019 |
| Characterization of NCGC1360 and NCGC1366 as Highly-Selective D2 Dopamine Receptor Antagonists and Lead Candidates for the Treatment of Neuropsychiatric Disorders AN Nilson, JN Hanson, T Poudel, AE Dulcey, RM Rodriguiz, KH Lee, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Characterization of the Binding Pocket for a Novel Positive Allosteric Modulator of the D1 Dopamine Receptor JN Hanson, AN Nilson, E Cohen, F Wang, J Rayadurgam, A Goldberg, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Enhancing Ligand Pharmacokinetics While Retaining Dopamine D4 Receptor Potency and Selectivity via Bioisosteric Substitution of Amide Linkers with 1, 2, 3-Triazoles M Alkhatib, AN Nilson, FM Jakobs, JN Hanson, J Ricchezza, S Jordan, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists AN Nilson, DE Felsing, P Wang, M Jain, J Zhou, J Allen bioRxiv, 2024.04. 15.589637, 2024 | | 2024 |
| Improved Pharmacokinetics of Dopamine D4 Receptor-Selective Ligands Trough Bioisosteric Replacement of Amide With 1, 2, 3-Triazole-Linked Analogues C Boateng, F Jakobs, J Hanson, A Nilson, A Mohammad, A Rodriguez, ... NEUROPSYCHOPHARMACOLOGY 48, 470-471, 2023 | | 2023 |
| Dopamine receptor divergence revealed using a common ligand DR Sibley, AN Nilson, AE Moritz, L Shi Trends in Pharmacological Sciences, 2023 | | 2023 |
| Bioisosteric Replacement of Amides Linkers with 1, 2, 3-Triazoles for Improved Pharmacokinetics Without Losing Dopamine D4 Receptor Potency or Selectivity D Panasis, M Alkhatib, J Saez, J Hanson, AN Nilson, FM Jacobs, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| Optimization of a Novel D2 Dopamine Receptor-Selective Antagonist into Lead Candidates for the Treatment of Neuropsychiatric Disorders A Nilson, J Hanson, AE Dulcey, X Wen, RB Free, RR Calvo, JJ Marugan, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| β-Arrestins Mediate Rapid 5-HT2A Receptor Endocytosis to Control the Efficacy and Kinetics of Serotonin and Psychedelic Hallucinogen Signaling H Smith, DE Felsing, A Nilson, JA Allen Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
